Ideally, assessment of PD-L1 expression in tumor tissues could predict ICI response; however, there is a growing interest in assessment of PD-L1 mRNA and protein levels in circulating extracellular vesicles, which may have the potential to predict response to anti-PD-1/PD-L1 antibodies [50, 51]. This evidence concerns the gene CD274 and neoplasm.